CytoSorbents Corporation has announced an update on the U.S. FDA regulatory status of its DrugSorb-ATR device. Despite the FDA upholding the De Novo denial, the agency found no safety issues with the device and proposed a potential path forward for market authorization. The company is actively engaging with the FDA to address the outstanding issues and explore this proposed path. The DrugSorb-ATR, an FDA Breakthrough Device, aims to aid heart attack patients requiring urgent coronary artery bypass graft surgery who face the risk of perioperative bleeding due to blood thinners. CytoSorbents remains committed to bringing this technology to U.S. and Canadian markets.